# The Relationship Between CMV* Reactivation and Anti-cytokine Treatment in Critical COVID-19 Patients

> **NCT05419206** · — · COMPLETED · sponsor: **Ramazan Gozukucuk** · enrollment: 167 (actual)

## Conditions studied

- COVID-19, Cytomegalovirus (CMV), Tocilizumab, Anakinra, Mortality

## Interventions

- **DIAGNOSTIC_TEST:** CMV DNA analysis

## Key facts

- **NCT ID:** NCT05419206
- **Lead sponsor:** Ramazan Gozukucuk
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-15
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-05-30
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05419206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05419206, "The Relationship Between CMV* Reactivation and Anti-cytokine Treatment in Critical COVID-19 Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05419206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*